Company intelligence / Profile preview

Yaoyou Pharmaceutical

Chongqing, Chongqing, China

Ownership: Private
Development stage: Other

Overview

YP05002, an oral small molecule GLP-1R agonist, is in Phase 1 clinical trials for chronic weight management, type 2 diabetes, obesity, and related conditions. Licensed exclusively to Pfizer globally with ongoing Phase 1 trial completion by Yaoyou.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

YP01001

Unknown

Partnerships

Pfizer (exclusive global license for YP05002)

Beyond the preview

Go deeper on Yaoyou Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yaoyou Pharmaceutical.

Explore the full profile